Buy GLP-2-T (Tirzepatide Analog) in the USA

Name: GLP2-T
Brand: BioInfinity Lab
SKU: GLP2-T
Availability: InStock

GLP-2-T is BioInfinity Lab's research-grade Tirzepatide analog — a dual GLP-1 + GIP receptor agonist studied across the SURPASS and SURMOUNT trial families. ≥99% HPLC purity, third-party COA, same-day USA shipping.

Dual-receptor research analog (GLP-1 / GIP)≥99% HPLC puritySame-day NY shipping

Available sizes — GLP2-T

Choose a size to continue to the product page where you can add to cart and complete checkout.

Need full product specs, batch COA, or related products? View the full GLP2-T product page →

GLP-2-T in published clinical research

Tirzepatide's published trial program — SURPASS for diabetes research and SURMOUNT for body-weight research — generated some of the most-cited recent literature in endocrinology. SURPASS-2 in NEJM (2021) compared Tirzepatide head-to-head with Semaglutide; SURMOUNT-1 in NEJM (2022) reports weekly-administration outcomes in the body-weight cohort.

GLP-2-T versus GLP-1-S in research head-to-head data

SURPASS-2 reported differentiated outcomes between Tirzepatide and Semaglutide on multiple research endpoints. Researchers replicating or extending these findings should refer directly to the NEJM publication (PMID 34324827) and follow their IRB-approved protocols.

Vial sizes and storage

Lyophilized 5 mg and 10 mg vials. Store lyophilized at −20 °C; reconstituted at 2–8 °C and use within 28 days.

USA shipping & COA

Every GLP-2-T lot ships from our New York facility with a Janoshik Analytical COA referenced on the product page. Same-day shipping on orders placed before 2 PM ET.

Research FAQ — GLP2-T

Frequently asked questions about this compound for laboratory researchers.

What is Tirzepatide / GLP-2-T?+

Tirzepatide is a dual-agonist research peptide that activates GLP-1 and GIP receptors. Published clinical-trial data describe glycemic and body-composition outcomes in research populations under controlled conditions.

Cited: PMID 34324827, PMID 35707975

How does Tirzepatide differ from Semaglutide in published research?+

SURPASS-2 (NEJM, 2021) compared Tirzepatide with Semaglutide head-to-head in research subjects with type 2 diabetes. The published data report differentiated effects on A1C and body-weight endpoints.

Cited: PMID 34324827

What dosing schedule is reported in Tirzepatide research?+

Published trial protocols administer Tirzepatide once weekly via subcutaneous injection at doses of 2.5–15 mg. Researchers should reference the cited publications and their IRB-approved protocols.

Cited: PMID 34324827, PMID 35707975

How is Tirzepatide stored?+

Lyophilized Tirzepatide is stored at −20 °C protected from light. Reconstituted solution is held at 2–8 °C, typically used within 28 days. See product COA for batch-specific details.

Published research references

Peer-reviewed literature relevant to GLP2-T research. Linked PubMed IDs open the original source.

[1]Tirzepatide once weekly for the treatment of obesity (SURMOUNT-1) — N Engl J Med (2022) · PMID 35707975
[2]Tirzepatide versus Semaglutide once weekly in patients with type 2 diabetes (SURPASS-2) — N Engl J Med (2021) · PMID 34324827
[3]Tirzepatide for type 2 diabetes: SURPASS-1 trial — Lancet (2021) · PMID 34108239

Reviewed by the BioInfinity Research Team

Content reviewed by our research and quality team — biochemistry-degreed reviewers working alongside our analytical lab partner (Janoshik Analytical). Every product page is cross-checked against the cited peer-reviewed literature and the current batch's third-party COA.

For laboratory research use only. Not for human or veterinary use. Content is informational and does not constitute medical advice.

Order GLP2-T from BioInfinity Lab

Same-day shipping from New York, ≥99% HPLC-verified purity, and a third-party COA on every lot.

Buy GLP2-T now

For laboratory research use only. Not for human or veterinary use.